Peroxisome proliferator-activated receptor γ (PPAR-γ) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria
Endocrine, cilt.25, sa.3, ss.207-214, 2004 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 25 Sayı: 3
- Basım Tarihi: 2004
- Doi Numarası: 10.1385/endo:25:3:207
- Dergi Adı: Endocrine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.207-214
- Anahtar Kelimeler: adiponectin, type 2 diabetes mellitus, proteinuria, insulin sensitivity, rosiglitazone
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Adiponectin appears to be an important modulator for metabolic and vascular diseases. A case-controlled study was designed to measure plasma adiponectin levels and investigate the effects of rosiglitazone on adiponectin levels in type 2 diabetic patients with proteinuria. Sixty-four patients (mean age, 46.1 ± 4.6 yr; 30 male, 34 female) and 26 healthy volunteers (mean age, 45.3 ± 4.8 yr; 14 male, 12 female) were included. Patients with proteinuria were treated with 4-mg/d rosiglitazone (n = 21, 10 males, 11 females) for 4 wk. Adiponectin levels in patients were significantly lower than those of controls (p < 0.001). There were significant negative correlations between adiponectin concentrations and insulin levels as well as homeostasis model assessment (HOMA) index in patient's group (r = -0.538, p < 0.001; r = -0.393, p = 0.001, respectively). There was also a significant negative correlation between plasma adiponectin concentrations and the degree of proteinuria (r = -0.526, p = 0.002). Plasma adiponectin levels in patients with proteinuria (n = 31; 3.91 ± 2.57 μg/mL) were significantly lower than those without proteinuria (n = 33; 10.15 ± 1.97 μg/mL) (p < 0.001). After the treatment period, adiponectin levels significantly increased (p < 0.001) and proteinuria, plasma insulin, and HOMA indexes significantly decreased in treatment group (p < 0.001, p < 0.001, p < 0.001, respectively). The results suggest that adiponectin is inversely correlated with proteinuria and treatment with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist rosiglitazone both corrects proteinuria and increases the low adiponectin levels in diabetic patients. © 2004 by Humana Press Inc. All rights of any nature whatsoever reserved.